WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13-14 May 2009

Vaccine

Volumn 28, Issue 52, 2010, Pages 8236-8245

  Ferguson, Morag ^a   Shin Jinho, J ^b   Knezevic, Ivana ^b   Minor, Philip ^a   Barrett, Alan ^c  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

Recommendations; World Health Organization; Yellow fever vaccine

Indexed keywords

YELLOW FEVER VACCINE;

ANTIBODY TITER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG QUALITY; DRUG SAFETY; HUMAN; MORBIDITY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; SWITZERLAND; VIREMIA; WORLD HEALTH ORGANIZATION; YELLOW FEVER;

GUIDELINES AS TOPIC; HUMANS; SWITZERLAND; VACCINES, ATTENUATED; WORLD HEALTH ORGANIZATION; YELLOW FEVER; YELLOW FEVER VACCINE;

EID: 78649725860     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.10.070     Document Type: Conference Paper

References (36)

1. World Health Organization International health regulations (2005) 2008, World Health Organization, Geneva, http://www.who.int/ihr/9789241596664/en/index.html.
2. World Health Organization Requirements for yellow fever vaccine (requirements for biological substances no. 3) 1998, WHO Expert Committee on Biological Standardization, World Health Organization, Geneva, Forty-sixth report. Annex 2 (WHO Technical Report Series No. 872). http://www.who.int/biologicals/publications/trs/areas/vaccines/yellow_fever/en/index.html.
3. Knezevic I., Stacey G., Petricciani J. WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007. Biologicals 2008, 36(May (3)):203-211.
4. Seagroatt V., Magrath D.I. A W.H.O. collaborative study of in vitro and in vivo methods for the assay of yellow fever vaccines. J Biol Stand 1983, 11(January (1)):47-54.
5. Ferguson M., Heath A. Collaborative study to assess the suitability of a candidate International Standard for yellow fever vaccine. Biologicals 2004, 32(December (4)):195-205.
6. World Health Organization International travel and health 2009 2009, World Health Organization, Geneva, http://www.who.int/ith/ITH_2009.pdf or http://www.who.int/ith/chapters/en/index.html.
7. Barrett A.D., Monath T.P., Barban V., Niedrig M., Teuwen D.E. 17D yellow fever vaccines: new insights A report of a workshop held during the World Congress on medicine and health in the tropics Marseille, France, Monday 12 September 2005. Vaccine 2007, 25(April (15)):2758-2765.
8. Gaucher D., Therrien R., Kettaf N., Angermann B.R., Boucher G., Filali-Mouhim A., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008, 205(December (13)):3119-3131.
9. Miller J.D., van der Most R.G., Akondy R.S., Glidewell J.T., Albott S., Masopust D., et al. Human effector and memory CD8+T cell responses to smallpox and yellow fever vaccines. Immunity 2008, 28(May (5)):710-722.
10. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10(January (1)):116-125.
11. Bae H.G., Domingo C., Tenorio A., de Ory F., Munoz J., Weber P., et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008, 197(June (11)):1577-1584.
12. Belsher J.L., Gay P., Brinton M., DellaValla J., Ridenour R., Lanciotti R., et al. Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease. Vaccine 2007, 25(December (50)):8480-8485.
13. Hayes E.B. Acute viscerotropic disease following vaccination against yellow fever. Trans R Soc Trop Med Hyg 2007, 101(October (10)):967-971.
14. Pulendran B., Miller J., Querec T.D., Akondy R., Moseley N., Laur O., et al. Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis 2008, 198(August (4)):500-507.
15. Meier K.C., Gardner C.L., Khoretonenko M.V., Klimstra W.B., Ryman K.D. A mouse model for studying viscerotropic disease caused by yellow fever virus infection. PLoS Pathog 2009, 5(October (10)):e1000614.
16. Whittembury A., Ramirez G., Hernandez H., Ropero A.M., Waterman S., Ticona M., et al. Viscerotropic disease following yellow fever vaccination in Peru. Vaccine 2009, 27(October (43)):5974-5981.
17. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine 2004, 22(June (17-18)):2103-2105.
18. Lindsey N.P., Schroeder B.A., Miller E.R., Braun M.M., Hinckley A.F., Marano N., et al. Adverse event reports following yellow fever vaccination. Vaccine 2008, 26(November (48)):6077-6082.
19. World Health, Organization Meeting of Global Advisory Committee on Vaccine Safety 18-19 June 2008. Wkly Epidemiol Rec 2008, 83(August (32)):287-292.
20. Struchiner C.J., Luz P.M., Dourado I., Sato H.K., Aguiar S.G., Ribeiro J.G., et al. Risk of fatal adverse events associated with 17DD yellow fever vaccine. Epidemiol Infect 2004, 132(October (5)):939-946.
21. Vasconcelos P.F., Luna E.J., Galler R., Silva L.J., Coimbra T.L., Barros V.L., et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet 2001, 358(July (9276)):91-97.
22. Galler R., Pugachev K.V., Santos C.L., Ocran S.W., Jabor A.V., Rodrigues S.G., et al. Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology 2001, 290(November (2)):309-319.
23. Engel A.R., Vasconcelos P.F., McArthur M.A., Barrett A.D. Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil. Vaccine 2006, 24(April (15)):2803-2809.
24. Galler R., Post P.R., Santos C.N., Ferreira I.I. Genetic variability among yellow fever virus 17D substrains. Vaccine 1998, 16(May-June (9-10)):1024-1028.
25. IABs scientific workshop on neurovirulence tests for live virus vaccines, January 31-February 1, 2005, Geneva. Biologicals 2006, 34(September (3)):233-236.
26. Marchevsky R.S., da Luz Leal M., Homma A., Coutinho E.S., Camacho L.A., Jabor A.V., et al. Molecular and phenotypic analysis of a working seed lot of yellow fever virus 17DD vaccine strain produced from the secondary seed lot 102/84 with an additional passage in chicken embryos. Biologicals 2006, 34(September (3)):191-197.
27. Camacho L.A., de Aguiar S.G., Freire Mda S., Leal Mda L., do Nascimento J.P., Iguchi T., et al. Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial. Rev Saude Publica 2005, 39(June (3)):413-420.
28. Camacho L.A., Freire Mda S., Leal Mda L., Aguiar S.G., Nascimento J.P., Iguchi T., et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica 2004, 38(October (5)):671-678.
29. Barban V., Girerd Y., Aguirre M., Gulia S., Petiard F., Riou P., et al. High stability of yellow fever 17D-204 vaccine: a 12-year restrospective analysis of large-scale production. Vaccine 2007, 25(April (15)):2941-2950.
30. Doblas A., Domingo C., Bae H.G., Bohorquez C.L., de Ory F., Niedrig M., et al. Yellow fever vaccine-associated viscerotropic disease and death in Spain. J Clin Virol 2006, 36(June (2)):156-158.
31. Huang H., Xu Z.J. One case of severe adverse event following to yellow fever vaccination. Chin J Intern Med 2005, 44:460-461.
32. Lopes O.S., Guimarães S.S., de Carvalho R. Studies on yellow fever vaccine. III. Dose response in volunteers. J Biol Stand 1988, 16(2):77-82.
33. Freestone D.S., Ferris R.D., Weinberg A.L., Kelly A. Stabilized 17D strain yellow fever vaccine: dose response studies, clinical reactions and effects on hepatic function. J Biol Stand 1977, 5(3):181-186.
34. Monath T.P., Cetron M.S., Teuwen DE Yellow fever vaccines. Vaccines 2008, 959-1055. Elsevier Inc., New York. 5th ed.
35. Pfister M., Kursteiner O., Hilfiker H., Favre D., Durrer P., Ennaji A., et al. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial. Am J Trop Med Hyg 2005, 72(March (3)):339-346.
36. World Health Organization Module 8: yellow fever. The immunological basis for immunization series 1993, World Health Organization, Geneva, WHO/EPI/GEN/93.18 http://www.who.int/immunization/documents/WHO_EPI_GEN_93.18/en/index.html.